From Psychiatry to Policy: Dr. Patrice A. Harris’s Multidimensional Impact on American Healthcare

Dr. Patrice A. Harris is a prominent figure in the field of medicine and public health, known for her dedication to addressing the critical issues surrounding healthcare access and equity. As a former president of the American Medical Association, Dr. Harris has been at the forefront of numerous initiatives aimed at improving health outcomes for […]

The Evolution of Community-Focused Fitness in a Post-Pandemic World

The Evolution of Community-Focused Fitness in a Post-Pandemic World In today’s rapidly evolving fitness landscape, industry veterans are noting a significant shift in consumer preferences toward more intimate, specialized workout environments. “Big-box gyms have re-opened, but many people no longer find them appealing,” explains a prominent fitness entrepreneur with decades of experience building successful boutique […]

Samuel Hahnemann’s Radical Idea

Marco Pharma Explains How Homeopathy Works Homeopathy has fascinated millions worldwide, offering a natural and holistic approach to healing based on the principle of “like treats like.” Originating in 19th-century Germany, it has since evolved into a global alternative medicine practice. Marco Pharma explores homeopathy’s journey from its revolutionary beginnings to its modern-day impact. Homeopathy […]

Anavex Life Sciences: Taking Charge in Alzheimer’s Disease Treatment

Anavex Life Sciences, a global biopharmaceutical company, is making strides in the medical world, specifically in Alzheimer’s disease treatment. The firm’s groundbreaking research and development efforts are propelling the industry forward, bringing hope to millions of patients across the globe.  One significant development is Anavex’s recent phase 2b/3 trial of their investigational therapy, blarcamesine. This […]

Blarcamesine Shows Promising Results in Phase 2 Extension Study by Anavex Life Sciences

Anavex Life Sciences, a leading biopharmaceutical company, has recently announced positive findings from the 48-week, open-label extension of their phase 2 study involving blarcamesine. This investigational agent has shown great potential in the treatment of Parkinson disease dementia (PDD), meeting both primary and secondary objectives in the study.  Despite facing delays due to the COVID-19 […]